Eli Lilly says its "triple-G" drug retatrutide beat Novo Nordisk's Ozempic in a diabetes study, adding to expectations that it will be one of Lilly's biggest growth drivers, STAT reports. STAT
STATLilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes studyData add to expectations that the drug will be one of Lilly’s greatest growth drivers.
What should we want to see in a head-to-head result, beyond a company's own announcement, before treating it as settled?
